In conjunction with the signing of the agreement,
Cilcare has been developing CIL001, a novel candidate drug for hearing loss treatment with auditory nerve protective effects. Currently, preparatory activities are underway to collect auditory data in patients with type 2 diabetes or mild cognitive impairment. From the fiscal year 2025, Phase 2a studies are planned to evaluate the safety and efficacy of CIL001 in patients with type 2 diabetes who have cochlear synaptopathy. Additionally, preclinical studies for CIL003 are currently underway.
Hearing loss is a major global health issue affecting around 1.5 billion people worldwide. Its incidence is rapidly increasing, with predictions that, by 2050, a quarter of the global population will experience varying degrees of hearing deficiency1. Hearing loss, particularly when it primarily affects the cochlear synapses 1 in the inner ear, is known as cochlear synaptopathy. This condition is also known to increase the risk of dementia in the elderly and is also an important complication of diabetes2. However, there are no effective treatments available, making it a condition with a high unmet need. The economic loss due to unaddressed hearing loss is said to be around
About
Cilcare is a biotech established in 2014, dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. Cilcare's mission is to ensure hearing impairments are addressed earlier and with precision, as they are often associated with chronic diseases from their very early stages. As a catalyst in the development of pharmaceuticals, medical devices, gene therapies, and cell therapies for hearing loss and tinnitus, Cilcare is driving transformative breakthroughs.
About CIL001
CIL001 is a novel candidate drug for hearing loss treatment with auditory nerve protective effect, licensed by
About Hearing loss
Hearing loss is a major global health issue affecting around 1.5 billion people worldwide. The significant surge in its incidence is attributed to the growing global population and an increase in the elderly demographic. If this trend continues, it will result in higher health insurance costs, social isolation, poverty, and a decrease in productivity, leading to substantial losses for society. One of the challenges with hearing loss is its gradual onset, making it difficult for patients to recognize and leading to low diagnosis rates. It is known to hinder various social activities, including communication with others, and is also considered a risk factor for central nervous system diseases.
Contact:
Web: https://www.shionogi.com
(C) 2024 Electronic News Publishing, source